Search

Your search keyword '"Parellada M"' showing total 657 results

Search Constraints

Start Over You searched for: Author "Parellada M" Remove constraint Author: "Parellada M"
657 results on '"Parellada M"'

Search Results

351. De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia.

352. Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis.

353. Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets.

354. White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?

355. Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study.

356. "A circle and a triangle dancing together": Alteration of social cognition in schizophrenia compared to autism spectrum disorders.

357. AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders.

358. One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry.

359. Auditory hallucinations in first-episode psychosis: A voxel-based morphometry study.

360. Neutrophil Count Is Associated With Reduced Gray Matter and Enlarged Ventricles in First-Episode Psychosis.

361. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study.

362. Author Correction: Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics.

363. Functional Gastrointestinal Disease in Autism Spectrum Disorder: A Retrospective Descriptive Study in a Clinical Sample.

364. Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer.

365. Neuroanatomical deficits shared by youth with autism spectrum disorders and psychotic disorders.

366. Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics.

367. Smoking does not impact social and non-social cognition in patients with first episode psychosis.

368. Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

369. The complex association between the antioxidant defense system and clinical status in early psychosis.

370. Cortical and Subcortical Brain Morphometry Differences Between Patients With Autism Spectrum Disorder and Healthy Individuals Across the Lifespan: Results From the ENIGMA ASD Working Group.

371. Gray matter changes and cognitive predictors of 2-year follow-up abnormalities in early-onset first-episode psychosis.

372. Randomized trial of omega-3 for autism spectrum disorders: Effect on cell membrane composition and behavior.

373. Modelling gene-environment interaction in first episodes of psychosis.

374. Atypical age-dependency of executive function and white matter microstructure in children and adolescents with autism spectrum disorders.

375. Developmental Differences Between Schizophrenia and Bipolar Disorder.

376. Insular pathology in young people with high-functioning autism and first-episode psychosis.

377. Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder.

378. Cannabis use, COMT, BDNF and age at first-episode psychosis.

379. Seeing the doctor without fear: www.doctortea.org for the desensitization for medical visits in Autism Spectrum Disorders.

380. Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis.

381. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project.

382. Age at First Episode Modulates Diagnosis-Related Structural Brain Abnormalities in Psychosis.

383. BDNF and NGF Signalling in Early Phases of Psychosis: Relationship With Inflammation and Response to Antipsychotics After 1 Year.

384. Executive function is affected in autism spectrum disorder, but does not correlate with intelligence.

385. Involvement of NRN1 gene in schizophrenia-spectrum and bipolar disorders and its impact on age at onset and cognitive functioning.

386. Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis.

387. Predictors of functional and clinical outcome in early-onset first-episode psychosis: the child and adolescent first episode of psychosis (CAFEPS) study.

388. Comparison between laparoscopic sacral hysteropexy and subtotal hysterectomy plus cervicopexy in pelvic organ prolapse: A pilot study.

389. Inflammation in schizophrenia: A question of balance.

390. Reduced Gyrification Is Related to Reduced Interhemispheric Connectivity in Autism Spectrum Disorders.

391. The affective dimension of early-onset psychosis and its relationship with suicide.

392. Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study.

393. Predictors of schizophrenia spectrum disorders in early-onset first episodes of psychosis: a support vector machine model.

394. Predictors of outcome in early-onset psychosis: a systematic review.

395. Synaptic, transcriptional and chromatin genes disrupted in autism.

396. Pro-/antiinflammatory dysregulation in early psychosis: results from a 1-year follow-up study.

397. Cortical morphology of adolescents with bipolar disorder and with schizophrenia.

398. A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis.

399. Polypharmacy with antidepressants in children and adolescents.

400. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations.

Catalog

Books, media, physical & digital resources